CRISPR Therapeutics AG annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
CRISPR Therapeutics AG Revenue Growth & History (CRSP)
CRISPR Therapeutics AG reported $3.5M in revenue for fiscal 2025, a decrease of 90.59% from the previous fiscal year.
View full CRISPR Therapeutics AG company overviewCRISPR Therapeutics AG annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.5M | −$33.8M | −90.59% |
| 2024 | 2024-12-31 | $37.3M | −$333.9M | −89.95% |
| 2023 | 2023-12-31 | $371.2M | $370.0M | +30885.48% |
| 2022 | 2022-12-31 | $1.2M | −$913.8M | −99.87% |
| 2021 | 2021-12-31 | $915.0M | $914.2M | +127154.94% |
| 2020 | 2020-12-31 | $719,000 | −$288.9M | −99.75% |
| 2019 | 2019-12-31 | $289.6M | $286.5M | +9169.85% |
| 2018 | 2018-12-31 | $3.1M | −$37.9M | −92.38% |
| 2017 | 2017-12-31 | $41.0M | $35.8M | +693.90% |
| 2016 | 2016-12-31 | $5.2M | $4.9M | +1990.69% |
| 2015 | 2015-12-31 | $247,000 | — | — |
CRISPR Therapeutics AG quarterly revenue
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.2M | $9.3M | +1041.37% |
| Q1 2026 | 2026-03-31 | $1.5M | $593,000 | +68.55% |
| Q4 2025 | 2025-12-31 | $864,000 | −$34.8M | −97.58% |
| Q3 2025 | 2025-09-30 | $889,000 | $287,000 | +47.67% |
| Q2 2025 | 2025-06-30 | $892,000 | $375,000 | +72.53% |
| Q1 2025 | 2025-03-31 | $865,000 | $361,000 | +71.63% |
| Q4 2024 | 2024-12-31 | $35.7M | −$165.5M | −82.26% |
| Q3 2024 | 2024-09-30 | $602,000 | $602,000 | — |
| Q2 2024 | 2024-06-30 | $517,000 | −$69.5M | −99.26% |
| Q1 2024 | 2024-03-31 | $504,000 | −$99.5M | −99.50% |
| Q4 2023 | 2023-12-31 | $201.2M | $201.2M | +3353333.33% |
| Q3 2023 | 2023-09-30 | $0 | −$94,000 | −100.00% |
| Q2 2023 | 2023-06-30 | $70.0M | $69.8M | +44203.80% |
| Q1 2023 | 2023-03-31 | $100.0M | $99.1M | +10538.30% |
| Q4 2022 | 2022-12-31 | $6,000 | −$12.9M | −99.95% |
| Q3 2022 | 2022-09-30 | $94,000 | −$730,000 | −88.59% |
| Q2 2022 | 2022-06-30 | $158,000 | −$900.5M | −99.98% |
| Q1 2022 | 2022-03-31 | $940,000 | $401,000 | +74.40% |
| Q4 2021 | 2021-12-31 | $12.9M | $12.5M | +3386.22% |
| Q3 2021 | 2021-09-30 | $824,000 | $676,000 | +456.76% |
| Q2 2021 | 2021-06-30 | $900.7M | $900.7M | +2046947.73% |
| Q1 2021 | 2021-03-31 | $539,000 | $382,000 | +243.31% |
| Q4 2020 | 2020-12-31 | $370,000 | −$76.6M | −99.52% |
| Q3 2020 | 2020-09-30 | $148,000 | −$211.8M | −99.93% |
| Q2 2020 | 2020-06-30 | $44,000 | −$274,000 | −86.16% |
| Q1 2020 | 2020-03-31 | $157,000 | −$171,000 | −52.13% |
| Q4 2019 | 2019-12-31 | $77.0M | $76.9M | +66870.43% |
| Q3 2019 | 2019-09-30 | $211.9M | $211.4M | +37542.63% |
| Q2 2019 | 2019-06-30 | $318,000 | −$770,000 | −70.77% |
| Q1 2019 | 2019-03-31 | $328,000 | −$1.0M | −75.85% |
| Q4 2018 | 2018-12-31 | $115,000 | −$32.2M | −99.64% |
| Q3 2018 | 2018-09-30 | $563,000 | −$1.8M | −76.41% |
| Q2 2018 | 2018-06-30 | $1.1M | −$2.5M | −69.63% |
| Q1 2018 | 2018-03-31 | $1.4M | −$1.3M | −49.76% |
| Q4 2017 | 2017-12-31 | $32.3M | $30.0M | +1279.05% |
| Q3 2017 | 2017-09-30 | $2.4M | $838,000 | +54.10% |
| Q2 2017 | 2017-06-30 | $3.6M | $2.8M | +350.57% |
| Q1 2017 | 2017-03-31 | $2.7M | $2.2M | +467.86% |
| Q4 2016 | 2016-12-31 | $2.3M | $2.1M | +848.99% |
| Q3 2016 | 2016-09-30 | $1.5M | — | — |
| Q2 2016 | 2016-06-30 | $795,000 | — | — |
| Q1 2016 | 2016-03-31 | $476,000 | — | — |
| Q4 2015 | 2015-12-31 | $247,000 | — | — |
CRISPR Therapeutics AG revenue growth trends
Over the last five reported fiscal years, revenue grew from $719,000 to $3.5M, a compound annual growth rate of 37.31%. CRISPR Therapeutics AG's latest reported quarter, Q2 2026, generated $10.2M in revenue, an increase of 1041.37% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review CRISPR Therapeutics AG source filings ↗